Esta página foi traduzida automaticamente e a precisão da tradução não é garantida. Por favor, consulte o versão em inglês para um texto fonte.

SGLT2 Inhibitor in Patients With Asymptomatic Moderate or Severe Aortic Stenosis (SAVE-AS)

13 de novembro de 2026 atualizado por: Sung-Ji Park, Samsung Medical Center

Multicenter, Randomized, Double-Blinded, Placebo-Controlled Trial to Assess the Efficacy and Safety of Sodium Glucose Cotransporter-2 Inhibitor in Patients With Aortic Valve Stenosis: SAVE-AS (SGLT2i Assessment Valvular Effect in AS)

Aortic stenosis (AS) is the most common valvular heart disease, and no medical therapy has been shown to slow its progression; treatment is limited to surgical or transcatheter aortic valve replacement once symptoms or left ventricular dysfunction develop. Sodium-glucose cotransporter-2 (SGLT2) inhibitors reduce cardiovascular death and heart failure hospitalization in patients with and without diabetes, and preclinical studies show that they suppress the inflammatory (NLRP3 inflammasome), fibrotic (TGF-beta/Smad), and oxidative-stress pathways that drive valve calcification. A recent observational study reported slower AS progression in patients treated with SGLT2 inhibitors.

SAVE-AS is a multicenter, prospective, randomized, double-blind, placebo-controlled, investigator-initiated superiority trial testing whether the SGLT2 inhibitor enavogliflozin (0.3 mg once daily) reduces the composite of all-cause death, aortic valve replacement, and hospitalization for heart failure in adults with asymptomatic moderate or severe aortic stenosis and preserved left ventricular ejection fraction (50% or higher). A total of 1,182 participants at 11 centers in the Republic of Korea will be randomized 1:1 to enavogliflozin or matching placebo, stratified by participating center and AS severity (moderate vs severe). Study treatment is given for 24 months, with follow-up visits at 2, 6, 12, 18, and 24 months and an end-of-treatment assessment at 25 months. Secondary outcomes include the individual components of the primary composite, cardiac death, echocardiographic AS severity, left ventricular mass, global longitudinal strain and ejection fraction, NT-proBNP, annual eGFR slope, and SGLT2 inhibitor-related adverse events. All clinical events are adjudicated by an independent clinical event adjudication committee, and safety is overseen by an independent data and safety monitoring board.

Visão geral do estudo

Status

Recrutamento

Descrição detalhada

Design: Prospective, multicenter (11 sites, Republic of Korea), randomized (1:1), double-blind, placebo-controlled, parallel-group, superiority, investigator-initiated trial. Randomization is performed centrally through an interactive web response system (IWRS) managed by an independent organization, stratified by participating center and baseline AS severity (moderate vs severe).

Population: Adults aged 19 years or older with asymptomatic (NYHA class I) moderate or severe aortic stenosis, defined as aortic valve area less than 1.5 cm2, peak aortic jet velocity 3 m/s or higher, or mean pressure gradient 25 mmHg or higher, with left ventricular ejection fraction 50% or higher. Patients meeting ACC/AHA or ESC/EACTS indications for aortic valve intervention, with very severe AS (peak velocity 5 m/s or higher or mean gradient 50 mmHg or higher), severe concomitant valve disease, eGFR below 30 mL/min/1.73 m2 or dialysis, type 1 diabetes, or SGLT2 inhibitor use within 3 months are excluded.

Intervention: Enavogliflozin 0.3 mg orally once daily or matching placebo for 24 months, on top of guideline-directed medical therapy per ACC/AHA/SCAI or ESC/EACTS recommendations. Concomitant medications may be adjusted at the investigator's discretion.

Schedule: Screening (day -90 to 0), baseline/randomization (day 0), visits at day 60 +/- 30, 180 +/- 30, 360 +/- 30, 540 +/- 30, and 720 +/- 30, and end-of-treatment assessment at day 750 +/- 90. Transthoracic echocardiography is performed at baseline, 12, and 24 months (and at 6 and 18 months in participants with severe AS at baseline). Laboratory tests (including eGFR), NT-proBNP and cardiac troponin T, ECG, and chest radiography are obtained at prespecified visits. Medication adherence is assessed at every visit. Clinical events are ascertained at each follow-up visit and at the end-of-treatment assessment at 25 months, and thereafter vital status and clinical events are ascertained by visit, telephone contact, or medical-record review until the end of study.

Sample size: Assuming an annual primary-event rate of 6% in the placebo group, a hazard ratio of 0.65, 3 years of accrual, 2 additional years of follow-up, 5% dropout, two-sided alpha of 0.05, and 80% power, 591 participants per group (1,182 total) are required (time-to-event analysis, log-rank test).

Analysis: Primary analysis by intention to treat; per-protocol analysis (adherence 70% or higher, no SGLT2 inhibitor use in the placebo group) as sensitivity analysis. Time-to-event outcomes are analyzed by Kaplan-Meier estimates, log-rank test, and Cox proportional-hazards models; continuous echocardiographic and laboratory outcomes by independent t-test. Participants lost to follow-up are censored. Prespecified subgroups: AS severity (moderate vs severe), age (below 70 vs 70 years or older), diabetes, hypertension, chronic kidney disease, and baseline global longitudinal strain. An interim analysis is planned when approximately 50% of the expected data have been collected, reviewed by the independent data and safety monitoring board.

Oversight: All primary and secondary clinical events are adjudicated by an independent Clinical Event Adjudication Committee. An independent Data and Safety Monitoring Board reviews all serious adverse events. Serious adverse events are reported to the principal investigator within 72 hours and to each site IRB per local requirements. The trial is conducted in accordance with the Declaration of Helsinki, ICH-GCP, and Korean GCP (KGCP).

Tipo de estudo

Intervencional

Inscrição (Estimado)

1182

Estágio

  • Fase 4

Contactos e Locais

Esta seção fornece os detalhes de contato para aqueles que conduzem o estudo e informações sobre onde este estudo está sendo realizado.

Contato de estudo

Estude backup de contato

Locais de estudo

      • Busan, Coréia do Sul
        • Ainda não está recrutando
        • Dong-A University Hospital
        • Investigador principal:
          • Kyung Hee Lim, MD, PhD
      • Changwon, Coréia do Sul
        • Ainda não está recrutando
        • Samsung Changwon Hospital
        • Investigador principal:
          • Mirae Lee, MD, PhD
      • Cheonan, Coréia do Sul
        • Ainda não está recrutando
        • Dankook University Hospital
        • Investigador principal:
          • Su Yeon Lee, MD, PhD
      • Gwangmyeong, Coréia do Sul
        • Ainda não está recrutando
        • Chung-Ang University Gwangmyeong Hospital
        • Investigador principal:
          • Eun Jeong Cho, MD, PhD
      • Seongnam, Coréia do Sul
        • Ainda não está recrutando
        • Seoul National University Bundang Hospital
        • Investigador principal:
          • Jiesuck Park, MD, PhD
      • Seoul, Coréia do Sul, 06351
        • Recrutamento
        • Samsung Medical Center
        • Contato:
        • Investigador principal:
          • Sung-Ji Park, MD, PhD
      • Seoul, Coréia do Sul
        • Ainda não está recrutando
        • Korea University Anam Hospital
        • Investigador principal:
          • So Ree Kim, MD, PhD
      • Seoul, Coréia do Sul
        • Ainda não está recrutando
        • Kangbuk Samsung Hospital
        • Investigador principal:
          • Jiwon Kim, MD, PhD
      • Seoul, Coréia do Sul
        • Ainda não está recrutando
        • Konkuk University Medical Center
        • Investigador principal:
          • Sung Hea Kim, MD, PhD
      • Seoul, Coréia do Sul
        • Ainda não está recrutando
        • Asan Medical Center, University of Ulsan College of Medicine
        • Investigador principal:
          • Dae-Hee Kim, MD, PhD
      • Seoul, Coréia do Sul
        • Ainda não está recrutando
        • Severance Hospital, Yonsei University College of Medicine
        • Investigador principal:
          • Chi Young Shim, MD, PhD

Critérios de participação

Os pesquisadores procuram pessoas que se encaixem em uma determinada descrição, chamada de critérios de elegibilidade. Alguns exemplos desses critérios são a condição geral de saúde de uma pessoa ou tratamentos anteriores.

Critérios de elegibilidade

Idades elegíveis para estudo

19 anos e mais velhos (Adulto, Adulto mais velho)

Aceita Voluntários Saudáveis

Não

Gêneros Elegíveis para o Estudo

Tudo

Descrição

Inclusion Criteria:

  • Able to understand the study protocol and provide written informed consent
  • Adults aged 19 years or older
  • Moderate or asymptomatic severe aortic stenosis, defined as all of the following:
  • Aortic valve area (AVA) less than 1.5 cm2, aortic valve peak velocity (Vmax) 3 m/s or higher, or aortic valve mean pressure gradient 25 mmHg or higher
  • Left ventricular ejection fraction 50% or higher
  • Asymptomatic, New York Heart Association (NYHA) functional class I

Exclusion Criteria:

  • Left ventricular ejection fraction below 50%
  • Indication for aortic valve intervention according to current ACC/AHA or ESC/EACTS guidelines
  • Symptomatic severe aortic stenosis
  • Severe stenosis or regurgitation of another valve, or concomitant severe aortic regurgitation
  • Very severe aortic stenosis (aortic valve Vmax 5 m/s or higher, or mean pressure gradient 50 mmHg or higher)
  • NYHA functional class II to IV
  • Use of an SGLT2 inhibitor within the previous 3 months
  • Known hypersensitivity to SGLT2 inhibitors
  • Estimated glomerular filtration rate below 30 mL/min/1.73 m2, or on dialysis
  • Type 1 diabetes mellitus
  • Pregnancy or breastfeeding
  • Liver disease with AST or ALT 2 or more times the upper limit of normal, or history of hepatic encephalopathy, esophageal varices, or portosystemic shunt
  • Life expectancy below 2 years, or inability to comply with the study protocol
  • Diabetic ketoacidosis
  • Current use of medications that may affect efficacy assessment (DPP-4 inhibitors, vitamin K, calcium supplements)
  • Sexually active women of childbearing potential who do not agree to use adequate contraception during the study
  • Participation in another clinical trial within the previous 1 month or 5 half-lives of the investigational product

Plano de estudo

Esta seção fornece detalhes do plano de estudo, incluindo como o estudo é projetado e o que o estudo está medindo.

Como o estudo é projetado?

Detalhes do projeto

  • Finalidade Principal: Tratamento
  • Alocação: Randomizado
  • Modelo Intervencional: Atribuição Paralela
  • Mascaramento: Quadruplicar

Armas e Intervenções

Grupo de Participantes / Braço
Intervenção / Tratamento
Experimental: Enavogliflozin

Enavogliflozin 0.3 mg film-coated tablet orally once daily for 24 months, in addition to guideline-directed medical therapy.

Sodium-glucose cotransporter-2 inhibitor, 0.3 mg film-coated tablet, taken orally once daily for 24 months.

Outros nomes:
  • Envlo
Comparador de Placebo: Placebo

Matching placebo tablet (identical in appearance) orally once daily for 24 months, in addition to guideline-directed medical therapy.

Matching placebo tablet identical in appearance to enavogliflozin, taken orally once daily for 24 months.

O que o estudo está medindo?

Medidas de resultados primários

Medida de resultado
Descrição da medida
Prazo
Composite of all-cause death, aortic valve replacement, or hospitalization for heart failure
Prazo: From randomization until the end of study (2 years after enrollment of the last participant), up to approximately 60 months

Time to first occurrence of any component of the composite: all-cause death; surgical or transcatheter aortic valve replacement; or hospitalization for heart failure, defined as presentation to an acute care facility requiring an overnight stay with symptoms and signs of heart failure and treatment with intravenous diuretics, vasodilators, or inotropes, mechanical fluid removal, intra-aortic balloon pump, or initiation/doubling of oral diuretics. All events are adjudicated by an independent clinical event adjudication committee.

From randomization until the end of study (2 years after enrollment of the last participant), up to approximately 60 months

Medidas de resultados secundários

Medida de resultado
Descrição da medida
Prazo
All-cause death
Prazo: From randomization until the end of study (2 years after enrollment of the last participant), up to approximately 60 months

Time to death from any cause after randomization.

From randomization until the end of study (2 years after enrollment of the last participant), up to approximately 60 months
Aortic valve replacement
Prazo: From randomization until the end of study (2 years after enrollment of the last participant), up to approximately 60 months

Time to first surgical or transcatheter aortic valve replacement after randomization.

From randomization until the end of study (2 years after enrollment of the last participant), up to approximately 60 months
Hospitalization for heart failure
Prazo: From randomization until the end of study (2 years after enrollment of the last participant), up to approximately 60 months

Time to first adjudicated hospitalization for heart failure after randomization (presentation to an acute care facility requiring an overnight stay with symptoms and signs of heart failure and treatment with intravenous diuretics, vasodilators, or inotropes, mechanical fluid removal, intra-aortic balloon pump, or initiation/doubling of oral diuretics).

From randomization until the end of study (2 years after enrollment of the last participant), up to approximately 60 months
Cardiac death
Prazo: From randomization until the end of study (2 years after enrollment of the last participant), up to approximately 60 months

Time to adjudicated cardiovascular death, including sudden cardiac death, death due to acute myocardial infarction, heart failure or cardiogenic shock, other cardiovascular causes, or death of unknown cause without an undisputed non-cardiac cause.

From randomization until the end of study (2 years after enrollment of the last participant), up to approximately 60 months
Change from baseline in aortic valve peak velocity
Prazo: Baseline, 12 months, and 24 months

Change in peak aortic jet velocity (m/s) measured by transthoracic echocardiography.

Baseline, 12 months, and 24 months
Change from baseline in mean transaortic pressure gradient
Prazo: Baseline, 12 months, and 24 months

Change in mean transaortic pressure gradient (mmHg) measured by transthoracic echocardiography.

Baseline, 12 months, and 24 months
Change from baseline in aortic valve area
Prazo: Baseline, 12 months, and 24 months

Change in aortic valve area (cm2) calculated by the continuity equation on transthoracic echocardiography.

Baseline, 12 months, and 24 months
Change from baseline in dimensionless index (velocity ratio)
Prazo: Baseline, 12 months, and 24 months

Change in the dimensionless index (velocity ratio), defined as the ratio of left ventricular outflow tract to transaortic velocity (or velocity-time integral), measured by transthoracic echocardiography; unitless.

Baseline, 12 months, and 24 months
Change from baseline in left ventricular mass
Prazo: Baseline, 12 months, and 24 months

Change in echocardiographic left ventricular mass (g).

Baseline, 12 months, and 24 months
Change from baseline in left ventricular global longitudinal strain
Prazo: Baseline, 12 months, and 24 months

Change in left ventricular global longitudinal strain (%) by speckle-tracking echocardiography.

Baseline, 12 months, and 24 months
Change from baseline in left ventricular ejection fraction
Prazo: Baseline, 12 months, and 24 months

Change in left ventricular ejection fraction (%) by transthoracic echocardiography.

Baseline, 12 months, and 24 months
Change from baseline in NT-proBNP
Prazo: Baseline, 12 months, and 24 months

Change in plasma N-terminal pro-B-type natriuretic peptide concentration (pg/mL).

Baseline, 12 months, and 24 months
Annual eGFR slope
Prazo: From baseline through 24 months

Mean slope of change in estimated glomerular filtration rate (CKD-EPI equation), expressed as mL/min/1.73 m2 per year.

From baseline through 24 months
Number of participants with at least one adverse event of special interest related to SGLT2 inhibition (safety)
Prazo: From first dose of study drug through 7 days after the last dose (up to approximately 25 months)

Number of participants experiencing one or more prespecified adverse events of special interest, reported as a single count per arm. Adverse events of special interest are: confirmed hypoglycemia (plasma glucose 70 mg/dL [3.9 mmol/L] or lower, or an event requiring assistance), urinary tract infection, genital infection, volume depletion, and acute kidney injury by KDIGO criteria.

From first dose of study drug through 7 days after the last dose (up to approximately 25 months)

Colaboradores e Investigadores

É aqui que você encontrará pessoas e organizações envolvidas com este estudo.

Patrocinador

Investigadores

  • Investigador principal: Sung-Ji Park, MD, PhD, Samsung Medical Center

Datas de registro do estudo

Essas datas acompanham o progresso do registro do estudo e os envios de resumo dos resultados para ClinicalTrials.gov. Os registros do estudo e os resultados relatados são revisados ​​pela National Library of Medicine (NLM) para garantir que atendam aos padrões específicos de controle de qualidade antes de serem publicados no site público.

Datas Principais do Estudo

Início do estudo (Real)

10 de junho de 2026

Conclusão Primária (Estimado)

1 de junho de 2031

Conclusão do estudo (Estimado)

1 de junho de 2031

Datas de inscrição no estudo

Enviado pela primeira vez

5 de novembro de 2026

Enviado pela primeira vez que atendeu aos critérios de CQ

13 de novembro de 2026

Primeira postagem (Real)

18 de novembro de 2026

Atualizações de registro de estudo

Última Atualização Postada (Real)

18 de novembro de 2026

Última atualização enviada que atendeu aos critérios de controle de qualidade

13 de novembro de 2026

Última verificação

1 de novembro de 2026

Mais Informações

Termos relacionados a este estudo

Outros números de identificação do estudo

  • 2025-07-028
  • KCT0012093 (Identificador de registro: Clinical Research Information Service (CRIS), Republic of Korea)

Plano para dados de participantes individuais (IPD)

Planeja compartilhar dados de participantes individuais (IPD)?

NÃO

Descrição do plano IPD

Individual participant data will not be shared outside the study group because the informed consent and institutional policy do not permit external release of participant-level data. Aggregate results will be published in a peer-reviewed journal and reported to ClinicalTrials.gov.

Informações sobre medicamentos e dispositivos, documentos de estudo

Estuda um medicamento regulamentado pela FDA dos EUA

Não

Estuda um produto de dispositivo regulamentado pela FDA dos EUA

Não

Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .

Se inscrever